Immunome, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
IMNM Nasdaq 2830 immunome.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunome, Inc.

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - Jun 11th, 2026 5:30 am
4 Biotech Stocks Investors Should Watch in 2026 - Jun 5th, 2026 8:54 am
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed? - Jun 4th, 2026 8:13 pm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 4th, 2026 2:02 pm
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - May 30th, 2026 6:00 am
Barclays initiates oncology-focused biotechs with positive outlook - May 28th, 2026 9:26 am
What Offers Immunome (IMNM) a Compelling Investment Opportunity? - May 18th, 2026 6:54 am
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors - May 11th, 2026 6:01 pm
Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success - May 11th, 2026 1:13 am
Techne (TECH) Misses Q3 Earnings and Revenue Estimates - May 6th, 2026 5:45 am
Exelixis (EXEL) Tops Q1 Earnings Estimates - May 5th, 2026 3:15 pm
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates - May 4th, 2026 5:30 pm
A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing - Apr 25th, 2026 5:04 am
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - Apr 4th, 2026 5:25 pm
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last? - Apr 1st, 2026 5:56 am
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - Mar 6th, 2026 3:11 pm
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - Mar 4th, 2026 10:32 am
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Mar 2nd, 2026 12:57 am
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Feb 24th, 2026 8:16 pm
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - Feb 22nd, 2026 11:32 am